Zobrazeno 1 - 10 of 948 pro vyhledávání: '"Ep, Diamandis"'
3
Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals
Autor: Cv, Obiezu, Erik Giltay, Magklara A, Scorilas A, Lj, Gooren, Yu H, Dj, Howarth, Ep, Diamandis
Publikováno v: Europe PubMed Central
The genes that encode prostate-specific antigen (PSA) and human glandular kallikrein (hK2) are up-regulated by androgens and progestins in cultured cells, but no published studies have described the effect of androgen administration in women on serum
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d1a9befa525bd0fd7299d8f6395ab79c
http://europepmc.org/abstract/med/10839777
Zobrazit plný text záznamu
4
Akademický článek
Guidance for securing approvals for new biomarkers: from discovery to clinical implementation.
Autor: Feilotter H; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada., Bruce C; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Diamandis EP; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Canada., Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Yousef GM; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Publikováno v: Critical reviews in clinical laboratory sciences [Crit Rev Clin Lab Sci] 2025 Jan; Vol. 62 (1), pp. 1-8. Date of Electronic Publication: 2024 Jul 31.
Zobrazit plný text záznamu
5
Akademický článek
Does Incretin Agonism Have Sustainable Efficacy?
Autor: Janket SJ; Retired Research Associate Professor, Boston University Goldman School of Dental Medicine, Boston, MA 02118, USA., Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada., Sohaei D; M.D., C.M. Candidate 2026, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A QT2, Canada., Tamimi F; Department of Restorative Dentistry, College of Dental Medicine, Qatar University, Doha P.O. Box 2713, Qatar., Meurman JH; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital and University of Helsinki, FI-00290 Helsinki, Finland., Diamandis EP; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5T 3L9, Canada.
Publikováno v: Cells [Cells] 2024 Nov 07; Vol. 13 (22). Date of Electronic Publication: 2024 Nov 07.
Zobrazit plný text záznamu
6
Editorial & Opinion
Cancer Biomarker Concentration Changes During Tumor Progression.
Autor: Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada., Diamandis EP; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
Publikováno v: EJIFCC [EJIFCC] 2024 Oct 30; Vol. 35 (3), pp. 206-209. Date of Electronic Publication: 2024 Oct 30 (Print Publication: 2024).
Zobrazit plný text záznamu
7
Akademický článek
The Unholy Grail of cancer screening: or is it just about the Benjamins?
Autor: Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Yousef GM; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.; Laboratory Medicine Program, 7989 University Health Network , Toronto, ON, Canada., Diamandis EP; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Canada.
Publikováno v: Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2024 Sep 23. Date of Electronic Publication: 2024 Sep 23.
Zobrazit plný text záznamu
8
Editorial & Opinion
The Feasibility for Screening for Ovarian Cancer.
Autor: Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Diamandis EP; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Publikováno v: EJIFCC [EJIFCC] 2024 Aug 08; Vol. 35 (2), pp. 132-135. Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024).
Zobrazit plný text záznamu
9
Akademický článek
Identification of brain-enriched proteins in CSF as biomarkers of relapsing remitting multiple sclerosis.
Autor: Wurtz LI; Medical Scientist Training Program, Mayo Clinic, Rochester, MN, USA.; Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA., Knyazhanskaya E; Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA., Sohaei D; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada., Prassas I; Mount Sinai Hospital, Toronto, Canada.; Laboratory Medicine Program, University Health Network, Toronto, Canada., Pittock S; Department of Neurology, Mayo Clinic, Rochester, MN, USA.; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA., Willrich MAV; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Saadeh R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Gupta R; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Atkinson HJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Grill D; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Stengelin M; Meso Scale Diagnostics, LLC. (MSD), Rockville, MD, USA., Thebault S; Department of Medicine and The Ottawa Research Institute, Ottawa, Canada.; Division of Multiple Sclerosis, Department of Neurology, The University of Pennsylvania, Philadelphia, USA., Freedman MS; Department of Medicine and The Ottawa Research Institute, Ottawa, Canada., Diamandis EP; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Canada., Scarisbrick IA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Scarisbrick.Isobel@mayo.edu.; Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, 55905, USA. Scarisbrick.Isobel@mayo.edu.
Publikováno v: Clinical proteomics [Clin Proteomics] 2024 Jun 16; Vol. 21 (1), pp. 42. Date of Electronic Publication: 2024 Jun 16.
Zobrazit plný text záznamu
10
Akademický článek
Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers.
Autor: Ghorbani A; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada., Chatanaka MK; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada., Avery LM; Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.; Department of Biostatistics, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada., Wang M; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Brown J; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Cohen R; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Gorham T; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Misaghian S; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Padmanabhan N; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Romero D; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Stengelin M; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Mathew A; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Sigal G; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Wohlstadter J; Meso Scale Diagnostics, LLC., Rockville, MD, USA., Horbinski C; Feinberg School of Medicine, Northwestern Medicine, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., McCortney K; Feinberg School of Medicine, Northwestern Medicine, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Xu W; Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.; Department of Biostatistics, The Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada., Zadeh G; MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada., Mansouri A; Department of Neurosurgery, Hershey Medical Center, Hershey, PA, USA.; Penn State Cancer Institute, Hershey Medical Center, Hershey, PA, USA., Yousef GM; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.; Laboratory Medicine Program, University Health Network, Toronto, Canada., Diamandis EP; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada. diamandis@lunenfeld.ca.; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. diamandis@lunenfeld.ca., Prassas I; Laboratory Medicine Program, University Health Network, Toronto, Canada. yprassas@gmail.com.
Publikováno v: Clinical proteomics [Clin Proteomics] 2024 Jun 15; Vol. 21 (1), pp. 41. Date of Electronic Publication: 2024 Jun 15.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje